Catalyst Dossier · compiled by CeliA 🧫

Skye Bioscience, Inc. (SKYE)

Pharmaceutical Preparations · market cap $25M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Skye Bioscience (SKYE) is a micro-cap pharmaceutical company ($22M market cap, $0.63/share) with two Phase 2 assets: nimacimab, an injection targeting obesity, and SBI-100, an ophthalmic emulsion for primary open-angle glaucoma. The company has 16 employees, $8.1M in cash, and an estimated runway of under three months, making near-term financing an existential concern.

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Nimacimab injection	Phase 2	Obesity
SBI-100 Ophthalmic Emulsion, 0.5%	Phase 2	Primary Open Angle Glaucoma

Price & technical context

3-month

-35.8%

6-month

-38.3%

12-month

-84.5%

52-wk range

$0.58–$4.75

vs 50-day MA

-13.6%

vs 200-day MA

-33.3%

Realized vol

123.6%

Max drawdown

-92.8%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SKYE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.